4 ms·
The article explain why studies with a placebo branch are important. You have a lot of known unknown and unknown unknown. In particular, as discussed in the art
by gus_massa 5y ago
The article explain why studies with a placebo branch are important. You have a lot of known unknown and unknown unknown. In particular, as discussed in the article, counting the number of cases/death is hard.
The main problem with the article is that all the vaccines are approved after a RCT were the vaccine is compared to a placebo. For example, look at the slide #6 in https://investors.biontech.de/static-files/53f0968a-279b-4f82-a2fc-d67dcb6e4e91 https://investors.biontech.de/static-files/53f0968a-279b-4f8... and more details in https://en.wikipedia.org/wiki/Pfizer%E2%80%93BioNTech_COVID-19_vaccine https://en.wikipedia.org/wiki/Pfizer%E2%80%93BioNTech_COVID-...
- charbonneau2 5y ago> The main problem with the article is that all the vaccines are approved after a RCT were the vaccine is compared to a placebo The author talks about effectiveness wrt mortality rates. No statistically significant difference was found during RCTs: > During the blinded, controlled period, 15 BNT162b2 and 14 placebo recipients died https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1.full.pdf+html https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v...